Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRASCOV: Lopinavir/ritonavir for COVID-19 Outpatients in Niger
NCT04409483Phase 3Withdrawn
- Sponsor
- Illumina
- Start
- Jun 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial of lopinavir + ritonavir in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Illumina. Primary endpoint: Hospitalization or death at 15 days. Planned start Jun 2020; status: withdrawn.
02
Drugs
lopinavir + ritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04409483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409483.